Flash Buy! Big Potential from This China-Centric Drug Developer
Today’s American biotech has been a big player in the Chinese market. In fact, it was the first U.S. biotech to receive a new drug approval in China before the United States. But now it’s the FDA’s turn to review the company’s drug, roxadustat, for the treatment of anemia in patients with chronic kidney disease. Strong clinical data makes the likelihood of approval very good.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Profit Alert
The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.